Fundz

Tolemy Bio closes $1.54M pre-seed round to advance AI-powered biological data platform Orbit.

PRIVATENov 13, 2026

Amount Raised

$1.54 Million

Round Type

Seed

Cambridge

Description

Tolemy Bio, an AI-in-bio company, closed its pre-seed funding round, bringing total funding to €1.4 million ($1.54 million). Co-founders Alex Ward and Caelan Anderson developed the company's commercial proposition around a pivot in the second half of 2025, focusing on converting biological data into AI-usable formats. The company built a software platform called Orbit as the foundation of their investor pitch. Tolemy has been named a finalist for 'Seed Raise of the Year' at LSX's Lifestar Awards 2026.

Quick answer

Tolemy Bio raised $1.54 Million in a Seed round, dated November 13, 2026. Tolemy Bio is based in Cambridge, England, United Kingdom.

How much did Tolemy Bio raise?
Tolemy Bio raised $1.54 Million in a Seed round on November 13, 2026.
What does Tolemy Bio do?
Tolemy Bio is a biotech startup that focuses on AI-enabled technology for cell biology research and biopharma development.
Where is Tolemy Bio based and how big is it?
Tolemy Bio is based in Cambridge, England, United Kingdom. Fundz records about 4 employees.
Who are the decision-makers at Tolemy Bio?
Fundz holds 1 contact at Tolemy Bio, including the Co-Founder. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Tolemy Bio, and when

A new round usually means Tolemy Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Tolemy Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Tolemy Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Tolemy Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Tolemy Bio

Location

Cambridge, England, United Kingdom

About

Tolemy Bio is a biotech startup that focuses on AI-enabled technology for cell biology research and biopharma development. The company is developing Orbit, a system designed to help researchers better understand and optimize living cells used in modern therapies. Tolemy Bio aims to streamline experimental workflows, which are currently fragmented and manual, to enhance the application of AI tools in drug development. The company's ultimate goal is to create a virtual-cell platform that facilitates more precise and data-driven experimentation in biopharma.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Tolemy Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsAlex W., Co-Founder hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Tolemy Bio's next move

See what Strategic adds

Tolemy Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.